Survival after Locoregional Treatments for Hepatocellular Carcinoma : A Cohort Study in Real-World Patients
Joint Authors
Calise, Fulvio
Marone, Giampiero
Signoriello, Giuseppe
Olivieri, Graziano
Annunziata, Annalisa
Di Costanzo, Giovanni Giuseppe
Piai, Guido
Signoriello, Simona
Lanzetta, Rosario
Gallo, Ciro
Di Maio, Massimo
Daniele, Bruno
Perrone, Francesco
Lama, Nicola
Gaeta, Giovanni B.
De Sio, Ilario
Visconti, Mario
Chiodini, Paolo
Fusco, Mario
Castaldo, Vincenzo
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-05-03
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Natural & Life Sciences (Multidisciplinary)
Medicine
Information Technology and Computer Science
Abstract EN
Evidence of relative effectiveness of local treatments for hepatocellular carcinoma (HCC) is scanty.
We investigated, in a retrospective cohort study, whether surgical resection, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), and transarterial embolization with (TACE) or without (TAE) chemotherapy resulted in different survival in clinical practice.
All patients first diagnosed with HCC and treated with any locoregional therapy from 1998 to 2002 in twelve Italian hospitals were eligible.
Overall survival (OS) was the unique endpoint.
Three main comparisons were planned: RFA versus PEI, surgical resection versus RFA/PEI (combined), TACE/TAE versus RFA/PEI (combined).
Propensity score method was used to minimize bias related to non random treatment assignment.
Overall 425 subjects were analyzed, with 385 (91%) deaths after a median followup of 7.7 years.
OS did not significantly differ between RFA and PEI (HR 1.11, 95% CI 0.79–1.57), between surgery and RFA/PEI (HR 0.95, 95% CI 0.64–1.41) and between TACE/TAE and RFA/PEI (HR 0.88, 95% CI 0.66–1.17).
5-year OS probabilities were 0.14 for RFA, 0.18 for PEI, 0.27 for surgery, and 0.15 for TACE/TAE.
No locoregional treatment for HCC was found to be more effective than the comparator.
Adequately powered randomized clinical trials are still needed to definitely assess relative effectiveness of locoregional HCC treatment.
American Psychological Association (APA)
Signoriello, Simona& Annunziata, Annalisa& Lama, Nicola& Signoriello, Giuseppe& Chiodini, Paolo& De Sio, Ilario…[et al.]. 2012. Survival after Locoregional Treatments for Hepatocellular Carcinoma : A Cohort Study in Real-World Patients. The Scientific World Journal،Vol. 2012, no. 2012, pp.1-7.
https://search.emarefa.net/detail/BIM-481157
Modern Language Association (MLA)
Signoriello, Simona…[et al.]. Survival after Locoregional Treatments for Hepatocellular Carcinoma : A Cohort Study in Real-World Patients. The Scientific World Journal No. 2012 (2012), pp.1-7.
https://search.emarefa.net/detail/BIM-481157
American Medical Association (AMA)
Signoriello, Simona& Annunziata, Annalisa& Lama, Nicola& Signoriello, Giuseppe& Chiodini, Paolo& De Sio, Ilario…[et al.]. Survival after Locoregional Treatments for Hepatocellular Carcinoma : A Cohort Study in Real-World Patients. The Scientific World Journal. 2012. Vol. 2012, no. 2012, pp.1-7.
https://search.emarefa.net/detail/BIM-481157
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-481157